Warrior Met Coal, Inc. HCC
79.16 USD +0.16 (+0.20%)
Regular-session close
79.16 0.00 0.00%
After hours · Nov 18, 4:00 PM ET
76.80 Day range 79.88
73.07 52-week range 110.28
- YTD
- -10.22%
- 1 year
- +1.42%
News
247wallst.com Mohnish Pabrai Has Nearly 95% of His Portfolio in Coal and Offshore Drilling, and His 13F Shows Just 4 Stocks Mohnish Pabrai's Pabrai Investment Funds filed its latest 13F on Nov. 13, and the filing shows just four stocks as of Sept. 30. Coal and offshore drilling make up 94.56% of the $362 million in…
businesswire.com Warrior Met Coal Provides Update on Third-Party Facility Incident BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today confirmed that a surface fire occurred Tuesday, November 17, 2026, at a third party-owned and…
marketbeat.com Warrior Met Coal Q3 Earnings Call Highlights Warrior Met Coal NYSE: HCC reported higher third-quarter revenue and profit as increased production from its Blue Creek mine and stronger steelmaking coal prices helped generate $139 million in free…benzinga.com UBS Maintains Buy on Warrior Met Coal, Lowers Price Target to $97 UBS analyst George Eadie maintains Warrior Met Coal (NYSE:HCC) with a Buy and lowers the price target from $102 to $97.
seekingalpha.com Warrior Met Coal, Inc. (HCC) Q3 2026 Earnings Call Transcript Warrior Met Coal, Inc. ( HCC ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Brian M. Chopin - Senior VP, Chief Accounting Officer & Controller Walter Scheller - CEO &…
zacks.com Warrior Met Coal (HCC) Lags Q3 Earnings Estimates Warrior Met Coal (HCC) came out with quarterly earnings of $0.93 per share, missing the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $0.7 per share a year ago.
benzinga.com Warrior Met Coal Q3 2026 Earnings Call Transcript Warrior Met Coal (NYSE:HCC) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
businesswire.com Warrior Reports Third Quarter 2026 Results BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) today announced results for the third quarter of 2026. Warrior is the leading dedicated U.S.-based…
seekingalpha.com Dividend Announcements: October 24-30, 2026 (Part 2 Of 2) I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify high-conviction opportunities. STX stands out with the highest…benzinga.com Warrior Met Coal Declares Special Dividend Of $2 Per Share Warrior Met Coal, Inc. (NYSE:HCC) ("Warrior" or the "Company") today announced that its board of directors has declared a special cash dividend of $2.00 per share to be paid on November 20, 2026, to
businesswire.com Warrior Met Coal Declares Special Cash Dividend BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today announced that its board of directors has declared a special cash dividend of $2.00 per share to…
zacks.com Warrior Met Coal (HCC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Warrior Met Coal (HCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
businesswire.com Warrior Announces Regular Quarterly Cash Dividend BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today announced that its board of directors has approved a regular quarterly cash dividend of $0.08…benzinga.com B. Riley Securities Maintains Buy on Warrior Met Coal, Lowers Price Target to $122 B. Riley Securities analyst Nick Giles maintains Warrior Met Coal (NYSE:HCC) with a Buy and lowers the price target from $123 to $122.
gurufocus.com Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a
gurufocus.com IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
gurufocus.com Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
gurufocus.com BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 [url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
gurufocus.com Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
businesswire.com Warrior Sets Date for Third Quarter 2026 Earnings Announcement and Investor Conference Call BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its third quarter 2026 investor conference call at 4:30 p.m. ET on Wednesday,…
seekingalpha.com Black Bear Value Partners Q3 2026 - Top 5 Businesses We Own Black Bear Value Fund, LP (the “Fund”) returned -10.3% in September, +2.5% in the quarter and +4.1% YTD. Builders FirstSource declined approximately 36% during the third quarter and was down roughly…
seekingalpha.com Warrior Met Coal: A Volume Story Still Priced Like A Coal Price Bet Warrior Met Coal now drives earnings growth through volume and cost reductions, not just coking coal price leverage. Blue Creek Mine's early ramp added a second product line, boosting Q2 sales to a…
247wallst.com Warren Buffett's Succession Triggers Search for His Spiritual Successors Warren Buffett's step back from Berkshire forces a harder question: which public companies actually run his playbook, and how close do any of them get to the real thing?
gurufocus.com Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu
